The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Implications of immunotherapy for personalized colorectal cancer treatments
Eric Christenson, MD, John Hopkins Medicine, Baltimore, MD, reflects on the Phase II trial (NCT03642067) of nivolumab and relatlimab in microsatellite stable (MSS) colorectal cancer (CRC) and their influence on future clinical practices. By understanding which combinations of therapeutics such are the most effective, clinicians can offer a wider range of personalized medicines for patients with MSS or microsatellite instable (MSI) high CRC. Patients with liver-sparing metastatic MSS CRC may also gain more benefit from immunotherapies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Seres Therapeutics
Research Funding – Haystack Oncology; Pfizer
Other Relationship – Natera
